L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease

Journal of Hypertension

Volumn 30, Issue 9, 2012, Pages 1834-1844

  Omori, Yosuke ^a,b   Ohtani, Tomohito ^a,b   Sakata, Yasushi ^a   Mano, Toshiaki ^a,b   Takeda, Yasuharu ^a,b   Tamaki, Shunsuke ^a,b   Tsukamoto, Yasumasa ^a,b   Kamimura, Daisuke ^a,b   Aizawa, Yoshihiro ^a   Miwa, Takeshi ^b   Komuro, Issei ^a   Soga, Tomoyoshi ^c   Yamamoto, Kazuhiro ^d  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

Author keywords

carnitine; diastolic heart failure; fibrosis; prostacyclin

Indexed keywords

ACYL COENZYME A DESATURASE; ANGIOTENSIN II; ARACHIDONIC ACID; CARNITINE; COLLAGEN; ORGANIC CATION TRANSPORTER 2; PROSTACYCLIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CAPILLARY ELECTROPHORESIS; CELL TRANSPORT; CONTROLLED STUDY; EXCRETION; FIBROBLAST; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART VENTRICULAR FIBROSIS; HIGH SODIUM INTAKE; HYPERTENSION; MALE; METABOLOMICS; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TIME OF FLIGHT MASS SPECTROMETRY;

EID: 84865529392     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283569c5a     Document Type: Article

References (56)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355:251-259. (Pubitemid 44079340)
2. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355:260-269. (Pubitemid 44088349)
3. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362:777-781. (Pubitemid 37093918)
4. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27:2338-2345. (Pubitemid 44453578)
5. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359:2456-2467.
6. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a populationbased cohort. J Am Coll Cardiol 1999; 33:1948-1955.
7. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98:2282-2289.
8. Doi R, Masuyama T, Yamamoto K, Doi Y, Mano T, Sakata Y, et al. Development of different phenotypes of hypertensive heart failure: systolic versus diastolic failure in Dahl salt-sensitive rats. J Hypertens 2000; 18:111-120. (Pubitemid 30093716)
9. Soga T, Ohashi Y, Ueno Y, Naraoka H, Tomita M, Nishioka T. Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J Proteome Res 2003; 2:488-494. (Pubitemid 37376843)
10. Ishii N, Nakahigashi K, Baba T, Robert M, Soga T, Kanai A, et al. Multiple high-throughput analyses monitor the response of E. coli to perturbations. Science 2007; 316:593-597. (Pubitemid 46683144)
11. Saito N, Ohashi Y, Soga T, Tomita M. Unveiling cellular biochemical reactions via metabolomics-driven approaches. Curr Opin Microbiol 2010; 13:358-362.
12. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 2009; 69:4918-4925.
13. Soga T, Baran R, Suematsu M, Ueno Y, Ikeda S, Sakurakawa T, et al. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J Biol Chem 2006; 281:16768-16776.
14. Morohashi M, Shimizu K, Ohashi Y, Abe J, Mori H, Tomita M, et al. P-BOSS: a new filtering method for treasure hunting in metabolomics. J Chromatogr A 2007; 1159:142-148. (Pubitemid 47048245)
15. Fujiwara K, Ishihama Y, Nakahigashi K, Soga T, Taguchi H. A systematic survey of in vivo obligate chaperonin-dependent substrates. EMBO J 2010; 29:1552-1564.
16. Nishio M, Sakata Y, Mano T, Ohtani T, Takeda Y, Miwa T, et al. Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Fail 2008; 10:446-453.
17. Ohtani T, Mano T, Hikoso S, Sakata Y, Nishio M, Takeda Y, et al. Cardiac steroidogenesis and glucocorticoid in the development of cardiac hypertrophy during the progression to heart failure. J Hypertens 2009; 27:1074-1083.
18. Toyofuku T, Hong Z, Kuzuya T, Tada M, Hori M. Wnt/frizzled-2 signaling induces aggregation and adhesion among cardiac myocytes by increased cadherin-beta-catenin complex. J Cell Biol 2000; 150:225-241. (Pubitemid 30480240)
19. Wang J, Chen H, Seth A, McCulloch CA. Mechanical force regulation of myofibroblast differentiation in cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2003; 285:H1871-H1881. (Pubitemid 37305927)
20. Takahashi R, Asai T, Murakami H, Murakami R, Tsuzuki M, Numaguchi Y, et al. Pressure overload-induced cardiomyopathy in heterozygous carrier mice of carnitine transporter gene mutation. Hypertension 2007; 50:497-502. (Pubitemid 47312235)
21. Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishikawa N, Nishio M, et al. AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension 2004; 43:686-691. (Pubitemid 38282448)
22. Nishio M, Sakata Y, Mano T, Yoshida J, Ohtani T, Takeda Y, et al. Therapeutic effects of angiotensin II type 1 receptor blocker at advanced stage of hypertensive diastolic heart failure. J Hypertens 2007; 25:455-461. (Pubitemid 46071945)
23. Yamamoto K, Masuyama T, Doi Y, Naito J, Mano T, Kondo H, et al. Noninvasive assessment of left ventricular relaxation using continuouswave Doppler aortic regurgitant velocity curve. Its comparative value to the mitral regurgitation method. Circulation 1995; 91:192-200.
24. Sugawara M, Nakano K. A method of analyzing regional myocardial function: mean wall stress-area strain relationship. Jpn Circ J 1987; 51:120-124. (Pubitemid 17046563)
25. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002; 55:76-82. (Pubitemid 34615941)
26. Takahashi M, Ueda S, Misaki H, Sugiyama N, Matsumoto K, Matsuo N, et al. Carnitine determination by an enzymatic cycling method with carnitine dehydrogenase. Clin Chem 1994; 40:817-821. (Pubitemid 24142862)
27. Nakamura T, Sugihara H, Kinoshita N, Yoneyama S, Azuma A, Nakagawa M. Can serum carnitine levels distinguish hypertrophic cardiomyopathy from hypertensive hearts? Hypertension 2000; 36: 215-219. (Pubitemid 30626991)
28. Gomez-Amores L, Mate A, Vazquez CM. L-carnitine transport in kidney of normotensive, Wistar-Kyoto rats: effect of chronic L-carnitine administration. Pharm Res 2003; 20:1133-1140. (Pubitemid 36951836)
29. Pu Q, Amiri F, Gannon P, Schiffrin EL. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. J Hypertens 2005; 23:401-409. (Pubitemid 40279644)
30. Yamamoto K, Takahashi Y, Mano T, Sakata Y, Nishikawa N, Yoshida J, et al. N-methylethanolamine attenuates cardiac fibrosis and improves diastolic function: inhibition of phospholipase D as a possible mechanism. Eur Heart J 2004; 25:1221-1229. (Pubitemid 38891572)
31. Bujak M, Kweon HJ, Chatila K, Li N, Taffet G, Frangogiannis NG. Agingrelated defects are associated with adverse cardiac remodeling in a mouse model of reperfused myocardial infarction. J Am Coll Cardiol 2008; 51:1384-1392. (Pubitemid 351443080)
32. Birnbaum Y, Ye Y, Rosanio S, Tavackoli S, Hu ZY, Schwarz ER, et al. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 2005; 65:345-355. (Pubitemid 40082476)
33. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226:497-509.
34. Metcalfe LD, Schmitz AA. Armour Industrial Chemical Co. The rapid preparation of fatty acid esters for gas chromatographic analysis. Anal Chem 1961; 33:363-364.
35. Yamamoto K, Masuyama T, Sakata Y, Doi R, Ono K, Mano T, et al. Local neurohumoral regulation in the transition to isolated diastolic heart failure in hypertensive heart disease: absence of AT1 receptor downregulation and 'overdrive' of the endothelin system. Cardiovasc Res 2000; 46:421-432. (Pubitemid 30319328)
36. Nishikawa N, Yamamoto K, Sakata Y, Mano T, Yoshida J, Miwa T, et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res 2003; 57: 766-774. (Pubitemid 36254870)
37. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28:2539-2550. (Pubitemid 47614269)
38. Yamaguchi H, Yoshida J, Yamamoto K, Sakata Y, Mano T, Akehi N, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004; 43:55-60. (Pubitemid 38045916)
39. Gallagher AM, Yu H, Printz MP. Bradykinin-induced reductions in collagen gene expression involve prostacyclin. Hypertension 1998; 32:84-88. (Pubitemid 28324129)
40. Kaneshige T, Saida Y, Tanaka R, Soda A, Fukushima A, Ida N, et al. Effect of long-term administration of a prostacyclin analogue (beraprost sodium) on myocardial fibrosis in Dahl rats. J Vet Med Sci 2007; 69:1271-1276.
41. Villarreal F, Epperson SA, Ramirez-Sanchez I, Yamazaki KG, Brunton LL. Regulation of cardiac fibroblast collagen synthesis by adenosine: roles for Epac and PI3K. Am J Physiol Cell Physiol 2009; 296:C1178-C1184.
42. Glaser C, Heinrich J, Koletzko B. Role of FADS1 and FADS2 polymorphisms in polyunsaturated fatty acid metabolism. Metabolism 2010; 59:993-999.
43. Guertl B, Noehammer C, Hoefler G. Metabolic cardiomyopathies. Int J Exp Pathol 2000; 81:349-372. (Pubitemid 32291178)
44. Calvani M, Benatti P, Mancinelli A, D'Iddio S, Giordano V, Koverech A, et al. Carnitine replacement in end-stage renal disease and hemodialysis. Ann N Y Acad Sci 2004; 1033:52-66. (Pubitemid 39656738)
45. Takahashi R, Okumura K, Asai T, Hirai T, Murakami H, Murakami R, et al. Dietary fish oil attenuates cardiac hypertrophy in lipotoxic cardiomyopathy due to systemic carnitine deficiency. Cardiovasc Res 2005; 68:213-223. (Pubitemid 41428418)
46. Romagnoli GF, Naso A, Carraro G, Lidestri V. Beneficial effects of L-carnitine in dialysis patients with impaired left ventricular function: an observational study. Curr Med Res Opin 2002; 18:172-175. (Pubitemid 34665755)
47. Pons R, Carrozzo R, Tein I, Walker WF, Addonizio LJ, Rhead W, et al. Deficient muscle carnitine transport in primary carnitine deficiency. Pediatr Res 1997; 42:583-587. (Pubitemid 27459462)
48. Hasegawa S, Yamamoto K, Sakata Y, Takeda Y, Kajimoto K, Kanai Y, et al. Effects of cardiac energy efficiency in diastolic heart failure: assessment with positron emission tomography with 11C-acetate. Hypertens Res 2008; 31:1157-1162.
49. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350:1953-1959.
50. Masuyama T, Yamamoto K, Sakata Y, Doi R, Nishikawa N, Kondo H, et al. Evolving changes in Doppler mitral flow velocity pattern in rats with hypertensive hypertrophy. J Am Coll Cardiol 2000; 36:2333-2338.
51. O'Brien D, Chunduri P, Iyer A, Brown L. L-carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats. Basic Clin Pharmacol Toxicol 2010; 106:296-301.
52. Garrelds IM, Elliott GR, Pruimboom WM, Zijlstra FJ, Bonta IL. Effects of carnitine and its congeners on eicosanoid discharge from rat cells: implications for release of TNFalpha. Mediators Inflamm 1993; 2:S57-S62. (Pubitemid 23324386)
53. Bueno R, Alvarez de Sotomayor M, Perez-Guerrero C, Gomez-Amores L, Vazquez CM, Herrera MD. L-carnitine and propionyl-L-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: different participation of NO and COX-products. Life Sci 2005; 77:2082-2097. (Pubitemid 41140450)
54. Miguel-Carrasco JL, Mate A, Monserrat MT, Arias JL, Aramburu O, Vazquez CM. The role of inflammatory markers in the cardioprotective effect of L-carnitine in L-NAME-induced hypertension. Am J Hypertens 2008; 21:1231-1237.
55. Rajasekar P, Palanisamy N, Anuradha CV. Increase in nitric oxide and reductions in blood pressure, protein kinase C beta II and oxidative stress by L-carnitine: a study in the fructose-fed hypertensive rat. Clin Exp Hypertens 2007; 29:517-530. (Pubitemid 350223251)
56. Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 1998; 273:20378-20382. (Pubitemid 28377603)